Brief: Hepatitis C/AASLD 2010

Introduction

Data from Phase III studies for Vertex/Johnson & Johnson’s telaprevir and Merck & Co’s boceprevir were the main focus at the AASLD meeting in November 2010. Since both drugs are likely to be approved at the same time, comparisons of their respective Phase III data, and likely usage in different patient populations, dominated the discussion.
Features and benefits

* In-depth discussion of pivotal Phase III data for telaprevir and boceprevir in treatment-naïve and treatment-experienced patients.* Analysis of the data presented from various key interferon-sparing studies.
Highlights

Safety and efficacy data from various trials assessing the use of interferon-sparing regimens suggest that interferon-sparing regimens are feasible. However, a greater insight into issues such as resistance is required in order to progress towards combination therapy with oral small molecule antivirals alone.
Your key questions answered

* Comparison and discussion of the data presented for the three most advanced HCV protease inhibitors at AASLD 2010.* Gain insight into the issues concerning the use of interferon-sparing regimens and the feasibility of such approaches.

[Studien Infos ausblenden]

KEY FINDINGS
The high unmet need for improved drugs in hepatitis C therapy has led to a highly active pipeline
ADVANCE and ILLUMINATE data indicate that telaprevir can cut treatment duration in half in treatment-naive patients
ADVANCE results confirm telaprevir’s efficacy in treatment-naive patients
Results from the ILLUMINATE study demonstrate that duration of therapy can be cut to 24 weeks in two thirds of treatment-naive genotype 1 patients
Top-line data from REALIZE study show improved efficacy rates in treatment-experienced patients receiving telaprevir
SPRINT-2 and RESPOND-2 results confirm boceprevir’s efficacy in treatment-naive and experienced patients
SPRINT-2 results demonstrate boceprevir’s efficacy in treatment-naive patients
RESPOND-2 data confirm boceprevir’s efficacy in treatment-experienced patients
Telaprevir and boceprevir will compete head to head after their expected launch in 2011
TMC435 demonstrates impressive efficacy in treatment-naive and -experienced patients
Results from the study investigating the combination of BMS-790052 and BMS-650032 (Bristol-Myers Squibb) suggest resistance will be a key hurdle for interferon-sparing regimens
Data from the study investigating the combination of BI 201335 and BI 207127 (Boehringer Ingelheim) indicates early antiviral activity
A paradigm shift in HCV therapy is unlikely to occur in the short- to mid-term future
BIBLIOGRAPHY
Literature

[Inhaltsverzeichnis ausblenden]